Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 34 for:    svane
Previous Study | Return to List | Next Study

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03047928
Recruitment Status : Recruiting
First Posted : February 9, 2017
Last Update Posted : October 31, 2018
Sponsor:
Information provided by (Responsible Party):
Inge Marie Svane, Herlev Hospital

Brief Summary:
Combination therapy is becoming more and more general in the treatment of oncological diseases. In this clinical trial combination the standard immunotherapeutic treatment; the programmed death 1 (PD-1) regulatory antibody Nivolumab and a peptide vaccine consisting of programmed death ligand 1 (PD-L1) and Indoleamine 2,3-dioxygenase (IDO) peptides will be tested in patients with metastatic melanoma. Patients will be treated with Nivolumab every second week as long as there is clinical benefit. The PD-L1/IDO peptide vaccine is given from start of Nivolumab and every second week for the first 6 vaccines and thereafter every fourth week up to 1 year.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: Nivolumab Biological: PD-L1/IDO peptide vaccine Phase 1 Phase 2

Detailed Description:

Background:

Huge advances have been made in the treatment of metastatic melanoma (MM) the past 5 years. Especially immunotherapy has shown promising results.

Cancer cells are naturally attacked by cells of the immune system, but can induce a state of tolerance whereby they escape from immune attack. This escape is brought about by many mechanisms. An important one is the programmed death pathway (PD-1/PD-L1). PD-L1 is commonly overexpressed on cancer cells. Interaction of PD-1 on activated T cells and PD-L1 on cancer cells lead to inhibition of the cytotoxic T cells. Another important mechanism is through overexpression of the metabolic enzyme IDO on cancer cells. Activation of IDO also inhibits cytotoxic T cells.

Investigators have recently identified spontaneous T cell reactivity against PD-L1 and IDO in the tumor microenvironment and in the peripheral blood of patients with MM and healthy donors. Both IDO and PD-L1 reactive CD8 T cells are cytotoxic and can kill cancer cells and immune regulatory cells in vitro.. Thus boosting specific T cells that recognize immune regulatory proteins such as IDO and PD-L1 may directly modulate immune regulation.

Due to distinct mechanisms of action, the combination of treatment with a monoclonal antibody targeting PD-1 (Nivolumab) and a vaccine with peptides against PD-L1 and IDO may have a synergistic effect.

Investigators have previously reported a phase I trial where, the IDO peptide was tested in 15 patients with MM in combination with Ipilimumab, and no grade 3-4 toxicity was seen. The PD-L1 peptide is currently being tested in a first-in-man study in patients with multiple myeloma.

Methods:

A two-step clinical phase I/II trial design will be used, starting out with a pilot study including 6 patients with MM to test feasibility and tolerability. If the treatment is found feasible the study will be extended to a phase II study with 24 patients. The objective is to describe anti-tumor immune responses and objective responses using RECIST 1.1.

Patients will be treated with Nivolumab in accordance with standard regimen, which involves outpatient IV infusions every second week as long as there is clinical benefit. The PD-L1/IDO peptide vaccine is given from start of Nivolumab and every second week for the first 6 vaccines and thereafter every fourth week up to 1 year. 15 vaccines will be administered in total.

Patients will be followed with clinical controls and diagnostic imaging every 12 weeks. Patients who receive all vaccines will have follow up after 3 and 6 months in parallel with standard of care treatment for Nivolumab.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Actual Study Start Date : February 22, 2018
Estimated Primary Completion Date : April 1, 2019
Estimated Study Completion Date : April 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Patient group

All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.

The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.

Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines.

Drug: Nivolumab
Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
Other Name: Opdivo

Biological: PD-L1/IDO peptide vaccine
The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
Other Name: IO102/IO103 peptide vaccine




Primary Outcome Measures :
  1. Number and type of reported adverse events [ Time Frame: 0-55 weeks ]
    Determine the safety of the combination therapy of Nivolumab and the PD-L1/IDO peptide vaccine for patients with metastatic melanoma by reporting adverse events according to CTCAE v. 4.0.


Secondary Outcome Measures :
  1. Treatment related immune responses [ Time Frame: Up to 24 months ]
    To evaluate the immunological impact of the combination therapy with Nivolumab and PD-L1/IDO peptide vaccine for patients with metastatic melanoma. ELISPOT and tetramer staining methods will be applied to identify PD-L1 and IDO specific T cells in the blood over time.

  2. Objective response rate [ Time Frame: Up to 24 months ]
    Clinical response will be evaluated by RECIST and PERCIST 1.1 and irRC

  3. Overall Survival [ Time Frame: Up to 24 months ]
    Overall Survival (OS), defined as time from treatment initiation to death, will be described with use of Kaplan Meier curve.

  4. Progression free survival [ Time Frame: Up to 24 months ]
    Progression free survival (PFS), defined as the time from treatment initiation to disease progression, relapse or death due to any cause, which ever comes first, will be described with Kaplan Meier curve.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18
  2. The patient has unrespectable or metastatic melanoma with progressive, persistent or recurrent disease on or following treatment with standard of care agents
  3. Patients belonging to one of the following patient groups will be enrolled:

    Cohort A: Anti PD-1/PD-L1 naïve patients (30 patients). The patient is a candidate for Nivolumab monotherapy. Prior anti‐PD‐1/anti‐PD-L1 antibody treatment is not allowed.

    OR Cohort B: Extension cohort (10 patients). Progressive disease ON anti‐PD‐1 monotherapy.Subjects should not have experienced serious and/or life‐threatening toxicity to antibody therapy.

    OR Cohort C: Extension cohort (10 patients). Progressive disease during follow up OFF anti-PD-1 after clinical benefit (SD/PR/CR) on anti‐PD‐1 therapy. Subjects should not have discontinued antibody therapy due to serious and/or lifethreatening toxicity

  4. At least one measurable parameter according to RECIST 1.1.
  5. The patient has an ECOG performance status of 0 or 1
  6. The patient is a female of childbearing potential with negative pregnancy test
  7. For women: Agreement to use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for at least 120 days after the treatment
  8. For men: Agreement to use contraceptive measures and agreement to refrain from donating sperm
  9. The patient has met the following hematological and biochemical criteria:

    1. AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases
    2. Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level > 1,5 ULN
    3. Serum creatinine ≤1,5 X ULN
    4. ANC (Absolute Neutrophil Count) ≥1,000/mcL
    5. Platelets ≥ 75,000 /mcL
    6. Hemoglobin ≥ 9 g/dL eller ≥ 5.6 mmol/L
  10. Signed declaration of content after oral and written information about the protocol.

Exclusion Criteria:

  1. The patient has not recovered to grade 0-1 from adverse events due to prior chemotherapy, radioactive or biological cancer therapy
  2. The patient has not recovered from surgery or is less than 4 weeks from major surgery
  3. The patient has a history of life-threatening or severe immune related adverse events on treatment with another immunotherapy and is considered to be at risk of not recovering
  4. The patient is expected to require any other form of systemic antineoplastic therapy while receiving the treatment
  5. The patient has a history of severe clinical autoimmune disease
  6. The patient has a history of pneumonitis, organ transplant, human immunodeficiency virus positive, active hepatitis B or hepatitis C
  7. The patient requires systemic steroids for management of immune-related adverse events experienced on another immunotherapy
  8. The patient has active CNS metastases and/or carcinomatous meningitis. However, patients with subclinical brain metastases < 1 cm can be included (maximum of 4 metastases < 1 cm). (Patients with previously treated brain metastases may participate provided they are clinically stable. Patients with untreated brain metastasis will be excluded)
  9. The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)
  10. The patient is pregnant or breastfeeding
  11. The patient is unable to voluntarily agree to participate by signed informed consent or assent
  12. The patient has an active infection requiring systemic therapy
  13. The patient has received a live virus vaccine within 30 days of planned start of therapy
  14. Known side effects to Montanide ISA-51
  15. Significant medical disorder according to investigator; e.g. severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus
  16. Concurrent treatment with other experimental drugs
  17. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.
  18. Severe allergy or anaphylactic reactions earlier in life

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03047928


Contacts
Layout table for location contacts
Contact: Inge Marie Svane, Prof., MD +4538683868 inge.marie.svane@regionh.dk
Contact: Julie Westerlin Kjeldsen, MD +4538683868 julie.westerlin.kjeldsen@regionh.dk

Locations
Layout table for location information
Denmark
Center for Cancer Immune Therapy, Dept. of Oncology/Hematology Recruiting
Herlev, Denmark, 2730
Contact: Inge Marie Svane, Prof., MD    +4538683868    inge.marie.svane@regionh.dk   
Contact: Julie Westerlin Kjeldsen, MD    +4538683868    julie.westerlin.kjeldsen@regionh.dk   
Herlev Hospital Recruiting
Herlev, Denmark, 2730
Contact: Julie W Kjeldsen, MD         
Sponsors and Collaborators
Inge Marie Svane
Investigators
Layout table for investigator information
Study Director: Inge Marie Svane, Prof., MD Center for Cancer Immune Therapy, Dept. of Oncology/Hematology, Copenhagen University Hospital Herlev, Herlev Ringvej 75, DK-2730
Principal Investigator: Julie Westerlin Kjeldsen, MD Center for Cancer Immune Therapy, Dept. of Oncology/Hematology, Copenhagen University Hospital Herlev, Herlev Ringvej 75, DK-2730

Layout table for additonal information
Responsible Party: Inge Marie Svane, MD, Professor, Herlev Hospital
ClinicalTrials.gov Identifier: NCT03047928     History of Changes
Other Study ID Numbers: MM1636
First Posted: February 9, 2017    Key Record Dates
Last Update Posted: October 31, 2018
Last Verified: October 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Vaccines
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents